Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | The association between mutations and comorbidities in patients with MDS

Guillermo Garcia-Manero • 10 Jun 2022
EHA 2022
Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the major causes of death in patients with low-risk myelodysplastic syndromes (MDS) and discusses the correlation between specific mutations and comorbidities in patients with MDS. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Guillermo Garcia-Manero

Potential strategies to prevent the evolution of CCUS to MDS
0:53
Potential strategies to prevent the evolution of CCUS to MDS
Guillermo Garcia-Manero • 7 Sep 2024
A total approach to MDS and unanswered questions in the field
2:38
A total approach to MDS and unanswered questions in the field
Guillermo Garcia-Manero • 7 Sep 2024
Key clinical trials in MDS taking place in the US
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
Sequencing of agents in LR-MDS
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Guillermo Garcia-Manero • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Guillermo Garcia-Manero • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Guillermo Garcia-Manero • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Guillermo Garcia-Manero • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals